Biora
This article was originally published in The Gray Sheet
Executive Summary
Plans to launch its PrefGel in the third quarter of 1998 following recent FDA clearance, the company says June 3. PrefGel, which is to be used by periodontists for conditioning exposed root surfaces during periodontal surgery, received European approval under the name PrepHgel earlier this year. PrefGel is the company's second dental therapy to reach the market. Its first product, Emdogain, for treatment of intrabony defects, was approved in 1996 ("The Gray Sheet" Oct. 21, 1996, I&W-4)...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.